Cargando…
Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals
The rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has be...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Authors.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332924/ https://www.ncbi.nlm.nih.gov/pubmed/34390647 http://dx.doi.org/10.1016/j.celrep.2021.109570 |
| _version_ | 1783732952454135808 |
|---|---|
| author | Lozano-Ojalvo, Daniel Camara, Carmen Lopez-Granados, Eduardo Nozal, Pilar del Pino-Molina, Lucía Bravo-Gallego, Luz Yadira Paz-Artal, Estela Pion, Marjorie Correa-Rocha, Rafael Ortiz, Alberto Lopez-Hoyos, Marcos Iribarren, Marta Erro Portoles, Jose Rojo-Portoles, Maria Pilar Ojeda, Gloria Cervera, Isabel Gonzalez-Perez, Maria Bodega-Mayor, Irene Montes-Casado, Maria Portoles, Pilar Perez-Olmeda, Mayte Oteo, Jesus Sanchez-Tarjuelo, Rodrigo Pothula, Venu Schwarz, Megan Brahmachary, Manisha Tan, Anthony Tanoto Le Bert, Nina Berin, Cecilia Bertoletti, Antonio Guccione, Ernesto Ochando, Jordi |
| author_facet | Lozano-Ojalvo, Daniel Camara, Carmen Lopez-Granados, Eduardo Nozal, Pilar del Pino-Molina, Lucía Bravo-Gallego, Luz Yadira Paz-Artal, Estela Pion, Marjorie Correa-Rocha, Rafael Ortiz, Alberto Lopez-Hoyos, Marcos Iribarren, Marta Erro Portoles, Jose Rojo-Portoles, Maria Pilar Ojeda, Gloria Cervera, Isabel Gonzalez-Perez, Maria Bodega-Mayor, Irene Montes-Casado, Maria Portoles, Pilar Perez-Olmeda, Mayte Oteo, Jesus Sanchez-Tarjuelo, Rodrigo Pothula, Venu Schwarz, Megan Brahmachary, Manisha Tan, Anthony Tanoto Le Bert, Nina Berin, Cecilia Bertoletti, Antonio Guccione, Ernesto Ochando, Jordi |
| author_sort | Lozano-Ojalvo, Daniel |
| collection | PubMed |
| description | The rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naive individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. In this study, we characterize SARS-CoV-2 spike-specific humoral and cellular immunity in naive and previously infected individuals during and after two doses of BNT162b2 vaccination. Our results demonstrate that, while the second dose increases both the humoral and cellular immunity in naive individuals, COVID-19 recovered individuals reach their peak of immunity after the first dose. These results suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2. |
| format | Online Article Text |
| id | pubmed-8332924 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | The Authors. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83329242021-08-04 Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals Lozano-Ojalvo, Daniel Camara, Carmen Lopez-Granados, Eduardo Nozal, Pilar del Pino-Molina, Lucía Bravo-Gallego, Luz Yadira Paz-Artal, Estela Pion, Marjorie Correa-Rocha, Rafael Ortiz, Alberto Lopez-Hoyos, Marcos Iribarren, Marta Erro Portoles, Jose Rojo-Portoles, Maria Pilar Ojeda, Gloria Cervera, Isabel Gonzalez-Perez, Maria Bodega-Mayor, Irene Montes-Casado, Maria Portoles, Pilar Perez-Olmeda, Mayte Oteo, Jesus Sanchez-Tarjuelo, Rodrigo Pothula, Venu Schwarz, Megan Brahmachary, Manisha Tan, Anthony Tanoto Le Bert, Nina Berin, Cecilia Bertoletti, Antonio Guccione, Ernesto Ochando, Jordi Cell Rep Report The rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naive individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. In this study, we characterize SARS-CoV-2 spike-specific humoral and cellular immunity in naive and previously infected individuals during and after two doses of BNT162b2 vaccination. Our results demonstrate that, while the second dose increases both the humoral and cellular immunity in naive individuals, COVID-19 recovered individuals reach their peak of immunity after the first dose. These results suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2. The Authors. 2021-08-24 2021-08-04 /pmc/articles/PMC8332924/ /pubmed/34390647 http://dx.doi.org/10.1016/j.celrep.2021.109570 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Report Lozano-Ojalvo, Daniel Camara, Carmen Lopez-Granados, Eduardo Nozal, Pilar del Pino-Molina, Lucía Bravo-Gallego, Luz Yadira Paz-Artal, Estela Pion, Marjorie Correa-Rocha, Rafael Ortiz, Alberto Lopez-Hoyos, Marcos Iribarren, Marta Erro Portoles, Jose Rojo-Portoles, Maria Pilar Ojeda, Gloria Cervera, Isabel Gonzalez-Perez, Maria Bodega-Mayor, Irene Montes-Casado, Maria Portoles, Pilar Perez-Olmeda, Mayte Oteo, Jesus Sanchez-Tarjuelo, Rodrigo Pothula, Venu Schwarz, Megan Brahmachary, Manisha Tan, Anthony Tanoto Le Bert, Nina Berin, Cecilia Bertoletti, Antonio Guccione, Ernesto Ochando, Jordi Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals |
| title | Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals |
| title_full | Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals |
| title_fullStr | Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals |
| title_full_unstemmed | Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals |
| title_short | Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals |
| title_sort | differential effects of the second sars-cov-2 mrna vaccine dose on t cell immunity in naive and covid-19 recovered individuals |
| topic | Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332924/ https://www.ncbi.nlm.nih.gov/pubmed/34390647 http://dx.doi.org/10.1016/j.celrep.2021.109570 |
| work_keys_str_mv | AT lozanoojalvodaniel differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT camaracarmen differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT lopezgranadoseduardo differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT nozalpilar differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT delpinomolinalucia differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT bravogallegoluzyadira differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT pazartalestela differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT pionmarjorie differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT correarocharafael differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT ortizalberto differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT lopezhoyosmarcos differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT iribarrenmartaerro differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT portolesjose differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT rojoportolesmariapilar differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT ojedagloria differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT cerveraisabel differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT gonzalezperezmaria differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT bodegamayorirene differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT montescasadomaria differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT portolespilar differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT perezolmedamayte differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT oteojesus differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT sancheztarjuelorodrigo differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT pothulavenu differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT schwarzmegan differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT brahmacharymanisha differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT tananthonytanoto differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT lebertnina differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT berincecilia differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT bertolettiantonio differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT guccioneernesto differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals AT ochandojordi differentialeffectsofthesecondsarscov2mrnavaccinedoseontcellimmunityinnaiveandcovid19recoveredindividuals |